true
Therapeutic Areas

Autoimmune Disease

Partner with BD to support your combination drug product development needs for autoimmune therapy

Contact Us
Medical professionals walking in hospital corridor

Autoimmune Disease

Autoimmune Disease

Autoimmune diseases occur as a result of the immune system attacking the body's own organs, tissues, and cells.1 Today, scientists know about more than 80 autoimmune diseases such as multiple sclerosis, lupus, inflammatory bowel disease, and rheumatoid arthritis. Many of these diseases require lifelong treatment to ease symptoms and reduce accompanying onset flares.2 There are no cures for autoimmune diseases yet, thus consistent, reliable, and accessible treatment is critical for managing patient's symptoms while minimizing the burden on patients' day-to-day lives.

Drug delivery systems play a critical role in managing autoimmune diseases. Pharmaceutical developers must take into consideration treatment delivery success as well as good usability.

Addressing Your Needs

Ensuring treatment delivery
success

Healthcare worker applies bandage after vaccination at home

Our range of portfolio offerings have been designed to ensure safe and effective injections.

BD NeopakTM XSiTM Glass Prefillable Syringe

With BD Neopak™ XtraFlow™ Glass Prefillable Syringe (with 8 mm needle and thin wall canula), help reduce intramuscular injection risk and reduce needle-related anxiety.3

BD Physioject Disposable Autoinjector Front View

The BD Physioject™ Disposable Autoinjector features a button mechanism to prevent accidental activation, 100% drug visibility through a 360° window, and automatic needle insertion.4,5,6

BD Libertas™ Wearable Injector and BD Evolve™ On-body Injector

The BD Libertas™ Wearable Injector and BD Evolve™ (On-body Injector have each been evaluated through multiple Human Factors studies to inform patient usability.


A range of offerings to break
formulation design barriers

Medical professionals discussing patient information indoors

A fully integrated portfolio of solutions and services enabling chronic diseases treatment across the formulation design space accounting for a wide range of volume, viscosity, and drug sensitivity needs.

BD NeopakTM XSiTM Glass Prefillable Syringe

BD Neopak™ XSi™ Glass Prefillable Syringe has been designed for improved integrity of the lubricant layer, reducing the subvisible particle level of biologic formulations, particularly for drugs that may be very sensitive to silicone oil.7

BD Neopak™ XtraFlow™ Glass Prefillable Syringe

The BD Neopak™ XtraFlow™ Glass Prefillable Syringe leverages an 8mm needle length combined with thinner wall technology. This combination offers a solution to balance injection force, time, and viscosity requirements without requiring patient experience trade-offs.3,8

BD Libertas™ Wearable Injector medical device close-up

BD has conducted over 50 pre-clinical and clinical studies to inform the design and development of the BD Libertas™ Wearable Injector demonstrating the feasibility of 2-10mL biologic injections into subcutaneous tissue.

BD EvolveTM On-body Injector

BD Evolve™ On-body Injector is intended to offer flexibility to serve design space requirements for continuous, episodic or delayed subcutaneous delivery of volumes up to 3mL.


BD self-injection systems designed
for the patient

  • Card Image

    With a patient centric design, the BD Physioject™ Disposable Autoinjector offers pharmaceutical companies a multitude of benefits.

  • BD Libertas™ Wearable Injector medical device close-up

    TThe BD Libertas™ Wearable Injector features a patient ready-to-use design requiring no end-user filling or assembly.

  • BD EvolveTM On-body Injector

    With the BD Evolve™ On-body Injector, BD aims to improve outcomes and patient experience by offering convenience, allowing for medication delivery outside of acute care settings.


Confidently partner with BD

  • Blue handshake icon with 70 percent progress circle

    ~70% of the top 100 pharmaceutical companies around the world rely BD Medical-Pharmaceutical Systems prefillable drug-delivery systems for a wide variety of therapeutic applications.10

  • World map with blue location markers overlay

    30+ drugs have been approved in a BD Neopak" Glass Pre llable Syringe(11), around the world.11

  • Healthcare Process Automation Infographic with Blue Icons

    End-to-end support along drug development process to serve our customers with value that goes beyond products, with expertise and support across medical, regulatory, and supply integration needs.


Choose BD to bring your drug to market

Backed by more than 60 years of experience, BD prefillable syringes and
services support medication delivery to benefit you, patients and clinicians.
 

Explore our products

 

BD SCF" PremiumCoat® Plunger Stoppers

Learn more

BD UltraSafe Plus" Passive Needle Guard

Learn more

BD Libertas" Wearable Injector

Learn more

BD Evolve" On-body Injector

Learn more
Autoplay: OFF

BD SCF" PremiumCoat® Plunger Stoppers

BD UltraSafe Plus" Passive Needle Guard

BD Libertas" Wearable Injector

BD Evolve" On-body Injector

Partner with BD

At BD, we're committed to partnering with you to help solve your drug delivery challenges. Are you ready to connect?

Contact us
For sales inquiries, technical support and customer support complete the following form:
References

PremiumCoat is a registered trademark of Aptar Pharma

  1. National Institute of Allergy and Infectious Diseases - Autoimmune Diseases - October 6, 2022 https://www.niaid.nih.gov/diseases-conditions/autoimmune-diseases
  2. National Institute of Environmental Health Sciences - Autoimmune Diseases - Last Reviewed: July 10, 2024 https://www.niehs.nih.gov/health/topics/conditions/autoimmune/index.cfm
  3. Pager et al. (2020 ), ˝User experience for manual injection of 2 mL viscous solutions is enhanced by a new prefillable syringe with staked 8mm ultra-thin wall needle", Expert Opinion on Drug Delivery, https: / /doi.org /10 .1080 /17425247 .2020 .1796630.* When compared to 12.7 mm special thin wall needl
  4. Physioject" Design Input Specification [Internal report]. Pont-de-Claix, FR: Becton, Dickinson and Company, 2014
  5. Physioject" external R&D document. Design Control Evidence of BD Physioject" with Hypak for BTH 1mL Long Size [external report]. Pont-de-Claix, FR: Becton, Dickinson and Company, 2021
  6. Physioject" Design Verification Report [Internal report]. Pont-de-Claix, FR: Becton, Dickinson and Company, 2014
  7. Depaz et al. Cross-Linked Silicone Coating: A Novel Prefilled Syringe Technology That Reduces Subvisible Particles and Maintains Compatibility with Biologics JOURNAL OF PHARMACEUTICAL SCIENCES 103:1384 1393, 2014
  8. Injection time and ejection force calculation [internal study ], Le Pont-de-Claix, France; Becton, Dickinson and Company, 2020
  9. https://www.arthritis.org/living-with-arthritis/tools-resources/ease-ofuse/health-and-wellness/bd-physioject-disposable-autoinjector.php
  10. BDM-PS financial file November 2023, "Actual FY23" Perimeter
  11. Registration status of drugs in BD Neopak" Glass Pre llable Syringe, May 31st, 2024 [Internal regulatory report]. Pont-de-Claix, FR: Becton Dickinson and Company; 2024.
Access our BD Webinar portal
true